$GILD Company News Investors warm up to Gilead's
Post# of 89400
Posted On: 12/21/2013 4:37:15 PM
$GILD Company News
Investors warm up to Gilead's test results; shares climb 5% by close 4:49 p.m. Dec. 18, 2013 - Russ Britt
Twitter hits record; Campbell, Starbucks head south 4:25 p.m. Dec. 10, 2013 - Sue Chang
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Nasdaq’s climb reflects vast shifts in global economy 10:19 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - Russ Britt
Dan Loeb ups stake in FedEx, Google, trims Yahoo 5:41 p.m. Nov. 14, 2013 - Sital S. Patel
Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 5:14 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 4:07 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 3:59 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 7:21 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 3:21 p.m. Oct. 10, 2013 - Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers 3:05 p.m. Oct. 10, 2013 - Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Gilead ends leukemia study after positive results 4:10 p.m. Oct. 9, 2013 - MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours 4:06 p.m. Oct. 9, 2013 - Wallace Witkowski
10 popular health-care stocks among hedge funds 11:34 a.m. Sept. 4, 2013 - Insider Monkey
2 Big Biotechs Moving Up On News 12:10 p.m. Dec. 20, 2013 - Seeking Alpha
Cramer's Mad Money - Themes That Will Work For 2014 (12/19/13) 6:23 a.m. Dec. 20, 2013 - Seeking Alpha
Jim Cramer's Top Stock Picks: AAPL CAT CX VMC CELG GILD 6:00 a.m. Dec. 20, 2013 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Some 'Buys' for the New Year 8:22 p.m. Dec. 19, 2013 - TheStreet.com
Positive Data on Gilead's Sovaldi - Analyst Blog 5:20 p.m. Dec. 19, 2013 - Zacks.com
Stock Market News for December 19, 2013 - Market News 10:06 a.m. Dec. 19, 2013 - Zacks.com
Cowen Forecasts Top 10 Potential Biotech Surprises for 2014 7:37 a.m. Dec. 19, 2013 - 247WallSt.com
Trade of the Day: Gilead Sciences (GILD) 4:08 a.m. Dec. 19, 2013 - InvestorPlace.com
Gilead's Sovaldi Holds Promise - Analyst Blog 4:30 p.m. Dec. 18, 2013 - Zacks.com
Gilead's Next Hepatitis C Drug A Hit In Trials 11:32 a.m. Dec. 18, 2013 - Investors Business Daily
Enanta falls after Gilead HCV data 10:56 a.m. Dec. 18, 2013 - Seeking Alpha
Gilead Offers Strong Data on Hepatitis C Treatment 10:12 a.m. Dec. 18, 2013 - WSJ.com
Gilead releases positive data from sofosbuvir/ ledipasvir HCV trials 9:30 a.m. Dec. 18, 2013 - Seeking Alpha
Waiting for a Signal From Gilead 9:00 a.m. Dec. 18, 2013 - RealMoney.com
Today's Pre-Market Trading Very Positive For Gilead (GILD) 8:58 a.m. Dec. 18, 2013 - TheStreet.com
Why Investors Are Writing Off Infinity Pharma 8:00 a.m. Dec. 18, 2013 - TheStreet.com
Piper Jaffray Top Stocks to Buy for 2014 7:44 a.m. Dec. 18, 2013 - 247WallSt.com
Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard 5:06 p.m. Dec. 17, 2013 - TheStreet.com
Label of Gilead's Complera Expanded - Analyst Blog 12:00 p.m. Dec. 16, 2013 - Zacks.com
Gilead Announces Health Canada Notice of Compliance for Sovaldi for Treatment of Chronic Hepatitis C 7:39 a.m. Dec. 16, 2013 - benzinga.com
Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Dec. 20, 2013 - ACCESSWIRE
Gilead Sciences Tops List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking 8:00 a.m. Dec. 19, 2013 - Marketwire
Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients 8:30 a.m. Dec. 18, 2013 - BusinessWire
FDA Consents, Pending Acquisition Approvals, Program Deployments, and Stock Movements - Research Report on Gilead, Elan, Agilent, Alkermes and Hospira 8:00 a.m. Dec. 18, 2013 - PR Newswire
Critical Insider Analysis: MGM Resorts International, Groupon Inc, Gilead Sciences, Barrick Gold Corporation 9:30 a.m. Dec. 17, 2013 - ACCESSWIRE
FDA Approvals, Dividends, Promoting Diversity, Result Publications and Acquisitions - Research Report on Gilead, St. Jude Medical, Cigna, Pharmacyclics, and LifePoint 8:00 a.m. Dec. 17, 2013 - PR Newswire
Health Canada Issues Notice of Compliance for Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C 8:30 a.m. Dec. 16, 2013 - BusinessWire
U.S. FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen Complera(R) for Patients Switching from a Stable Regimen 4:30 p.m. Dec. 13, 2013 - BusinessWire
HealthStat Rx: Curing Hepatitis C (HCV) With Confidence 10:07 a.m. Dec. 12, 2013 - BusinessWire
Here to Track Insider Trading of Gilead Sciences, Microsoft, Halliburton 8:55 a.m. Dec. 11, 2013 - PR Newswire
Clinical Study Results, Stock Price Movements, and Acquisitions - Research Report on Gilead, Life Technologies, Jazz Pharmaceuticals, CSI, and Smith & Nephew 8:00 a.m. Dec. 11, 2013 - PR Newswire
Final Hour Buzz: Gilead Sciences, MannKind Corporation, Facebook Inc, Tiger Oil and Energy 2:46 p.m. Dec. 10, 2013 - ACCESSWIRE
Interest Stock Analysis: Gilead Sciences, Acura Pharmaceuticals, Barnes & Noble, Micron Technology 11:00 a.m. Dec. 9, 2013 - ACCESSWIRE
Stock Price Updates, FDA 510(k) Clearances, Conference Presentation and Resignations - Research Report on Gilead, Oculus Innovative Sciences, ARCA biopharma, Arena Pharma, and Tonix Pharma 8:00 a.m. Dec. 9, 2013 - PR Newswire
Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma 6:00 p.m. Dec. 8, 2013 - BusinessWire
Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia 6:30 p.m. Dec. 7, 2013 - BusinessWire
U.S. Food and Drug Administration Approves Gilead's Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C 4:19 p.m. Dec. 6, 2013 - BusinessWire
Gilead Sciences to Present at the NASDAQ OMX 30th Investor Program on Tuesday, December 3 5:00 p.m. Dec. 2, 2013 - BusinessWire
Critical Alerts For General Electric, Gilead Sciences, Morgan Stanley, Qualcomm, and Adobe Released By InvestorsObserver 9:31 a.m. Dec. 2, 2013 - PR Newswire
Market Expert Opinion: Gilead Sciences, NPS Pharma, InterMune, and Halozyme Therapeutics 8:40 a.m. Dec. 2, 2013 - PR Newswire
Investors warm up to Gilead's test results; shares climb 5% by close 4:49 p.m. Dec. 18, 2013 - Russ Britt
Twitter hits record; Campbell, Starbucks head south 4:25 p.m. Dec. 10, 2013 - Sue Chang
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Nasdaq’s climb reflects vast shifts in global economy 10:19 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - Russ Britt
Dan Loeb ups stake in FedEx, Google, trims Yahoo 5:41 p.m. Nov. 14, 2013 - Sital S. Patel
Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 5:14 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 4:07 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 3:59 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 7:21 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 3:21 p.m. Oct. 10, 2013 - Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers 3:05 p.m. Oct. 10, 2013 - Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Gilead ends leukemia study after positive results 4:10 p.m. Oct. 9, 2013 - MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours 4:06 p.m. Oct. 9, 2013 - Wallace Witkowski
10 popular health-care stocks among hedge funds 11:34 a.m. Sept. 4, 2013 - Insider Monkey
2 Big Biotechs Moving Up On News 12:10 p.m. Dec. 20, 2013 - Seeking Alpha
Cramer's Mad Money - Themes That Will Work For 2014 (12/19/13) 6:23 a.m. Dec. 20, 2013 - Seeking Alpha
Jim Cramer's Top Stock Picks: AAPL CAT CX VMC CELG GILD 6:00 a.m. Dec. 20, 2013 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Some 'Buys' for the New Year 8:22 p.m. Dec. 19, 2013 - TheStreet.com
Positive Data on Gilead's Sovaldi - Analyst Blog 5:20 p.m. Dec. 19, 2013 - Zacks.com
Stock Market News for December 19, 2013 - Market News 10:06 a.m. Dec. 19, 2013 - Zacks.com
Cowen Forecasts Top 10 Potential Biotech Surprises for 2014 7:37 a.m. Dec. 19, 2013 - 247WallSt.com
Trade of the Day: Gilead Sciences (GILD) 4:08 a.m. Dec. 19, 2013 - InvestorPlace.com
Gilead's Sovaldi Holds Promise - Analyst Blog 4:30 p.m. Dec. 18, 2013 - Zacks.com
Gilead's Next Hepatitis C Drug A Hit In Trials 11:32 a.m. Dec. 18, 2013 - Investors Business Daily
Enanta falls after Gilead HCV data 10:56 a.m. Dec. 18, 2013 - Seeking Alpha
Gilead Offers Strong Data on Hepatitis C Treatment 10:12 a.m. Dec. 18, 2013 - WSJ.com
Gilead releases positive data from sofosbuvir/ ledipasvir HCV trials 9:30 a.m. Dec. 18, 2013 - Seeking Alpha
Waiting for a Signal From Gilead 9:00 a.m. Dec. 18, 2013 - RealMoney.com
Today's Pre-Market Trading Very Positive For Gilead (GILD) 8:58 a.m. Dec. 18, 2013 - TheStreet.com
Why Investors Are Writing Off Infinity Pharma 8:00 a.m. Dec. 18, 2013 - TheStreet.com
Piper Jaffray Top Stocks to Buy for 2014 7:44 a.m. Dec. 18, 2013 - 247WallSt.com
Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard 5:06 p.m. Dec. 17, 2013 - TheStreet.com
Label of Gilead's Complera Expanded - Analyst Blog 12:00 p.m. Dec. 16, 2013 - Zacks.com
Gilead Announces Health Canada Notice of Compliance for Sovaldi for Treatment of Chronic Hepatitis C 7:39 a.m. Dec. 16, 2013 - benzinga.com
Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Dec. 20, 2013 - ACCESSWIRE
Gilead Sciences Tops List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking 8:00 a.m. Dec. 19, 2013 - Marketwire
Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients 8:30 a.m. Dec. 18, 2013 - BusinessWire
FDA Consents, Pending Acquisition Approvals, Program Deployments, and Stock Movements - Research Report on Gilead, Elan, Agilent, Alkermes and Hospira 8:00 a.m. Dec. 18, 2013 - PR Newswire
Critical Insider Analysis: MGM Resorts International, Groupon Inc, Gilead Sciences, Barrick Gold Corporation 9:30 a.m. Dec. 17, 2013 - ACCESSWIRE
FDA Approvals, Dividends, Promoting Diversity, Result Publications and Acquisitions - Research Report on Gilead, St. Jude Medical, Cigna, Pharmacyclics, and LifePoint 8:00 a.m. Dec. 17, 2013 - PR Newswire
Health Canada Issues Notice of Compliance for Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C 8:30 a.m. Dec. 16, 2013 - BusinessWire
U.S. FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen Complera(R) for Patients Switching from a Stable Regimen 4:30 p.m. Dec. 13, 2013 - BusinessWire
HealthStat Rx: Curing Hepatitis C (HCV) With Confidence 10:07 a.m. Dec. 12, 2013 - BusinessWire
Here to Track Insider Trading of Gilead Sciences, Microsoft, Halliburton 8:55 a.m. Dec. 11, 2013 - PR Newswire
Clinical Study Results, Stock Price Movements, and Acquisitions - Research Report on Gilead, Life Technologies, Jazz Pharmaceuticals, CSI, and Smith & Nephew 8:00 a.m. Dec. 11, 2013 - PR Newswire
Final Hour Buzz: Gilead Sciences, MannKind Corporation, Facebook Inc, Tiger Oil and Energy 2:46 p.m. Dec. 10, 2013 - ACCESSWIRE
Interest Stock Analysis: Gilead Sciences, Acura Pharmaceuticals, Barnes & Noble, Micron Technology 11:00 a.m. Dec. 9, 2013 - ACCESSWIRE
Stock Price Updates, FDA 510(k) Clearances, Conference Presentation and Resignations - Research Report on Gilead, Oculus Innovative Sciences, ARCA biopharma, Arena Pharma, and Tonix Pharma 8:00 a.m. Dec. 9, 2013 - PR Newswire
Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma 6:00 p.m. Dec. 8, 2013 - BusinessWire
Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia 6:30 p.m. Dec. 7, 2013 - BusinessWire
U.S. Food and Drug Administration Approves Gilead's Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C 4:19 p.m. Dec. 6, 2013 - BusinessWire
Gilead Sciences to Present at the NASDAQ OMX 30th Investor Program on Tuesday, December 3 5:00 p.m. Dec. 2, 2013 - BusinessWire
Critical Alerts For General Electric, Gilead Sciences, Morgan Stanley, Qualcomm, and Adobe Released By InvestorsObserver 9:31 a.m. Dec. 2, 2013 - PR Newswire
Market Expert Opinion: Gilead Sciences, NPS Pharma, InterMune, and Halozyme Therapeutics 8:40 a.m. Dec. 2, 2013 - PR Newswire
(0)
(0)